Home > Insider Trading > Filing (0001209191-15-067369)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1557421	Ignyta Inc.	RXDX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1602223	City Hill Venture Partners I, Llc	11575 Sorrento Valley Road Suite 200 San Diego CA 92121		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-08-19	6,500	$12.95	3,323,168	No	4	P	Direct
Common Stock	Acquisiton	2015-08-19	240	$13.05	3,323,408	No	4	P	Direct
Common Stock	Acquisiton	2015-08-20	1,700	$12.69	3,325,108	No	4	P	Direct
Common Stock	Acquisiton	2015-08-20	40	$12.77	3,325,148	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

Reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $12.73 to $13.14. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $12.50 to $13.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.